La Jolla's (LJPC) Phase 2 trial of its GCS-100 chronic kidney disease drug "met its primary efficacy endpoint of a statistically significant improvement in kidney function." A 1.5 mg/m2 dose led to a statistically significant increase in estimated glomerular filtration rate relative to a a placebo. (PR)
Secondary endpoints were also achieved, and 117 out of 121 enrolled patients completed treatment.
La Jolla: "We hope to use these results as a platform for further investigation not only in chronic kidney disease but also in other diseases where tissue fibrosis plays a central role."
Wedbush launched coverage with an Outperform last month, arguing there was a "70% probability of a positive outcome" for the trial.